Our best-in-field platform leverages nearly a decade of proprietary advances that enable multiple RNA-targeting small molecule drug discovery and development strategies tailored for different interventional opportunities across a wide range of disease indications.
Partnership
Advancing Through Partnership
Ribometrix has a proven track record of collaborative execution across multiple partnerships and disease indications.
Why You Should Partner With Us
What Our Partners Have Said
-
“Genentech is committed to exploring innovative approaches to drug targets that are difficult to address with conventional approaches,” said James Sabry, M.D., Ph.D., global head of Pharma Partnering, Roche. “Ribometrix has built capabilities to drug specific RNAs, and we look forward to a productive collaboration to explore this emerging area of science.”
-
“Targeting RNA is a potentially powerful new approach for developing small molecule therapeutics, and Ribometrix has developed an innovative technology for the accelerated discovery of selective candidates in this new space,” said Mark Bunnage, Senior Vice President and Global Head of Research at Vertex. “This partnership adds a novel mechanism to our internal toolkit which has the potential to enhance our ongoing research capabilities and support the expansion of our pipeline of transformative medicines in serious diseases.” Ribometrix is collaborating with Vertex to discover and develop RNA-targeted small molecule therapeutics against up to three therapeutic programs.”
Platform
A Best-in-Field Drug Discovery Engine
These capabilities have driven 3 main areas of platform enablement:
1. Rational Target Prioritization (The “RTP” Approach)
2. Discovery and development of inherently functional RNA binders (RNA Modulation through Binding-Alone)
3. Engineering function into strongly selective “silent” binders (BOLSTR™: Bioactivity Optimization of Ligands Silently Targeting RNAs)
Our People
Ribometrix Leadership & Team
Meet the Ribometrix team, where every individual is valued as part of a collaborative community sharing a common focus on advancing the field of modulating RNA biology to discover and develop transformative small-molecule drugs.
Our Latest Updates
View All News-
Ribometrix Strengthens Leadership, Appoints William S. Marshall, Ph.D., as Chief Executive Officer and Katie Warner, Ph.D., as Chief Scientific Officer
-
Ribometrix Present Data Supporting Potential of eIF4E Program in KRAS Mutant Non-Small Cell Lung Cancer at ESMO 2024
-
Ribometrix To Present Data Supporting Potential of eIF4E Program in KRAS Mutant Non-Small Cell Lung Cancer at ESMO 2024